Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.47 |
| ▸ | OGA | O60502 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20756303 | 1.00 | MAOA (0.50) | MAOAMAOBMEN1KMT2AKDM4E | |
| SCHEMBL13180668 | 0.87 | MEN1 (0.63) | MAOAMAOBMEN1KMT2AKDM4E | |
| SCHEMBL19018977 | 0.86 | MEN1 (0.47) | MAOAMAOBMEN1KMT2AKDM4E | |
| SCHEMBL10311208 | 0.84 | MAOA (0.52) | MAOAMAOBMEN1KMT2AKDM4E | |
| SCHEMBL30561536 | 0.81 | MAOA (0.57) | MAOAMAOBMEN1KMT2AKDM4E | |
| SCHEMBL1083820 | 0.81 | MAOA (0.57) | MAOAMAOBMEN1KMT2AKDM4E | |
| SCHEMBL28886162 | 0.81 | MAOA (0.48) | MAOAMAOBMEN1KMT2AKDM4E | |
| SCHEMBL23102118 | 0.79 | ACACB (0.44) | NOTUM | |
| SCHEMBL22817021 | 0.79 | DRD1 (0.47) | HRH3 | |
| SCHEMBL2632967 | 0.79 | KCNH2 (0.52) | KMT2AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3683219-A1 | COMPOUND INHIBITING BUTYRYLCHOLINESTERASE | Julius-Maximilians-Universität Würzburg (DE) | 2020-07-22 | — | — | EP | disclosed |
| WO-2019036024-A1 | 2-(1,1 '-BIPHENYL)-1 H-BENZO[D]IMIDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS APELIN AND APJ AGONISTS FOR TREATING CARDIOVASCULAR DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-02-21 | — | — | WO | disclosed |
| EP-2945943-B1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-30 | — | — | EP | disclosed |
| WO-2017207556-A2 | UREA MOTIF CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS ANTIBACTERIAL DRUGS | Technische Universität München (DE) | 2017-12-07 | — | — | WO | disclosed |
| US-20120322722-A1 | Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use | THE UNIVERSITY OF MANCHESTER (GB) | 2012-12-20 | — | — | US | disclosed |
| US-20120309698-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-06 | — | — | US | disclosed |
| US-20120238546-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-09-20 | — | — | US | disclosed |
| US-20120129846-A1 | GAMMA SECRETASE MODULATORS | Merck, Sharp & Dohme, Corp. | 2012-05-24 | — | — | US | disclosed |
| US-8163720-B2 | Pyrrolidinyl phenyl sulphonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100256128-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-10-07 | — | — | US | disclosed |
| US-7524844-B2 | Dipeptidyl peptidase IV inhibitors, process for their preparation and compositions containing them | GLENMARK PHARMACEUTICALS S.A. (CH) | 2009-04-28 | — | — | US | disclosed |
| WO-2007128460-A1 | SUBSTITUTED 3 -AMINO-4 -HYDROXY PYRROLIDINES COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-11-15 | — | — | WO | disclosed |
| EP-1849781-A1 | Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2007-10-31 | — | — | EP | disclosed |
| US-20070232608-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-10-04 | — | — | US | disclosed |
| WO-2006088949-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE | MIIKANA THERAPEUTICS, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309698-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | MAOA 1379/4885MAOB 1256/4885MEN1 4650/4885 |
| US-20120129846-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | MAOA 1838/4885MAOB 2160/4885MEN1 2572/4885 |
| US-20100256128-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | MAOA 1838/4885MAOB 2160/4885MEN1 2572/4885 |
| US-20070232608-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | DPP4, DPP3, DPP7 | MAOA 2697/4885MAOB 2530/4885MEN1 3385/4885 |
| US-20120238546-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | MAOA 1481/4885MAOB 1595/4885MEN1 3509/4885 |
| US-20120322722-A1 | Pyruvamide Compounds as Inhibitors of Dust Mite Group 1 Peptidase Allergen and Their Use | PREP, DPEP1, PEPD | MAOA 789/4885MAOB 2390/4885MEN1 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.